Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?

被引：1
|
作者：
Park, Jihye [1 ,2 ]
机构：
[1] Yonsei Univ, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Inst Gastroenterol, Coll Med, Seoul, South Korea
来源：
INTESTINAL RESEARCH | 2022年 / 20卷 / 01期
关键词：
NECROSIS FACTOR THERAPY; CROHNS-DISEASE; RISK-FACTORS; SURGERY; VEDOLIZUMAB;
D O I：
10.5217/ir.2021.00170
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [21] Predicting and preventing complications in children with inflammatory bowel disease
    Grover, Zubin
    TRANSLATIONAL PEDIATRICS, 2019, 8 (01) : 70 - 76
  • [22] Pulmonary complications in patients with inflammatory bowel disease
    Kuzela, L
    Vavrecka, A
    Prikazska, M
    Drugda, B
    Hronec, J
    Senkova, A
    Drugdova, M
    Oltman, M
    Novotna, T
    Brezina, M
    Kratky, A
    Kristufek, P
    HEPATO-GASTROENTEROLOGY, 1999, 46 (27) : 1714 - 1719
  • [23] Hepatic Complications of Inflammatory Bowel Disease
    Mahfouz, Mahmoud
    Martin, Paul
    Carrion, Andres F.
    CLINICS IN LIVER DISEASE, 2019, 23 (02) : 191 - +
  • [24] Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease
    Lightner, Amy L.
    Loftus, Edward V., Jr.
    McKenna, Nicholas P.
    Raffals, Laura E.
    CURRENT DRUG TARGETS, 2019, 20 (13) : 1317 - 1322
  • [25] Factors Associated with Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease
    Abadir, Alexander
    Troia, Angela
    Said, Hyder
    Tarugu, Spurthi
    Billingsley, Benjamin C.
    Sairam, Nathan
    Minchenberg, Scott B.
    Owings, Anna H.
    Parker, Adam M.
    Brousse, Brandon
    Carlyle, Alexander
    Owens, Bobby R.
    Hosseini-Carroll, Pegah
    Galeas-Pena, Michelle
    Frasca, Joseph
    Glover, Sarah C.
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (08) : 2796 - 2803
  • [26] Extraintestinal Manifestations of Inflammatory Bowel Disease Are Associated With Increased Biologic Cycling
    Alizadeh, Madeline
    Ali, Osman
    Cross, Raymond K.
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [27] Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
    Sorrentino, Dario
    Nguyen, Vu Q.
    Love, Kim
    DIGESTIVE DISEASES, 2021, 39 (06) : 626 - 633
  • [28] Review article: safety of new biologic agents for inflammatory bowel disease in the liver
    Magri, Salvatore
    Chessa, Luchino
    Demurtas, Mauro
    Cabras, Francesco
    Mocci, Giammarco
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (05) : 623 - 630
  • [29] Role of hospitalization for inflammatory bowel disease in the post-biologic era
    Soriano, Celine R.
    Powell, Charleston R.
    Chiorean, Michael V.
    Simianu, Vlad V.
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (26) : 7632 - 7642
  • [30] Biologic therapies in inflammatory bowel disease
    Flamant, M.
    Bourreille, A.
    REVUE DE MEDECINE INTERNE, 2007, 28 (12): : 852 - 861
12345